Sirolimus for beginners: the complete starter guide

Last updated 2026-07-30

What is sirolimus and is it the same as rapamycin?

Sirolimus and rapamycin are the same molecule. Rapamycin was the original name, discovered in a soil bacterium (Streptomyces hypogaeus) isolated from Easter Island (Rapa Nui) in the 1970s. When the drug was developed commercially, it was renamed sirolimus, and that's the name on the FDA label. You'll see both terms used interchangeably in research and online, and there's no chemical difference between them ^[1]. Sirolimus is FDA-approved for a narrow set of uses: preventing organ rejection in kidney transplant patients, and, in different formulations, treating a rare lung disease (lymphangioleiomyomatosis) and certain vascular and skin conditions under the brand names Fyarro and Hyftor ^[2]. It is not approved for aging, longevity, or healthspan extension in any form. Every use for that purpose is off-label, meaning a doctor is prescribing an approved drug for a purpose the FDA never reviewed or cleared. That distinction matters more than it sounds like it should. Off-label prescribing is legal and common in medicine, but it means the safety and dosing data that exist (from transplant patients on daily, higher-dose regimens) don't map cleanly onto the low-dose, once-weekly protocols people use for longevity. Nobody has run the trial that would tell you if those protocols work in humans.

What does sirolimus actually do in the body (the mTOR mechanism)?

Sirolimus blocks a protein complex called mTOR (mechanistic target of rapamycin), specifically mTORC1. mTOR is a central nutrient-sensing pathway: when nutrients and growth signals are abundant, mTORC1 activity is high and cells favor growth and protein synthesis over repair and recycling. When mTORC1 is suppressed, cells shift toward autophagy, the process of clearing out damaged proteins and organelles ^[3]. The longevity theory rests on this switch. Caloric restriction, one of the most reproducible ways to extend lifespan in lab animals, also suppresses mTORC1. Rapamycin is, in effect, a pharmacological shortcut to some of that same signaling state, without requiring you to actually eat less. That's the appeal: a pill that might mimic part of what caloric restriction does metabolically. The catch is that mTORC1 isn't just an aging dial. It's also central to immune cell proliferation and wound healing, which is exactly why the drug works as an immunosuppressant and why suppressing it chronically carries real tradeoffs, covered below.

What's the actual evidence that sirolimus extends lifespan?

The strongest evidence is in mice, not humans, and the gap between those two facts is the single most important thing to understand about this drug. The NIA's Interventions Testing Program (ITP) is the anchor study. It's a multi-site, NIH-funded program specifically designed to test candidate longevity compounds in genetically diverse mice under standardized conditions at three labs (Jackson Laboratory, University of Michigan, University of Texas Health Science Center). Rapamycin was tested starting in 2006 and has been retested in multiple cohorts since. In the original 2009 Nature report, rapamycin fed starting at 600 ppm in food beginning at 20 months of age (roughly equivalent to late middle age in humans) extended median lifespan by 9% in males and 14% in females, even though dosing started relatively late in life ^[4]. Later ITP cohorts, using earlier starting ages and different doses, found larger effects, up to roughly 23% median lifespan extension in some female cohorts, with effects generally dose-dependent ^[5]. This is one of the most consistently replicated findings in mouse lifespan research, which is unusual; most claimed longevity interventions fail to replicate across the ITP's three independent sites. What doesn't exist: any completed human randomized controlled trial measuring lifespan or all-cause mortality as an endpoint for rapamycin used in healthy adults. The trials that do exist in humans are small, short, and use surrogate markers, not survival. A notable example is a 2014 Novartis-funded trial (Mannick et al., Science Translational Medicine) that gave older adults an mTOR inhibitor (an analog of rapamycin, not rapamycin itself) for 6 weeks and found improved response to influenza vaccination, a proxy for immune function, not a lifespan or mortality outcome ^[2]. That's genuinely interesting immunology. It is not evidence that rapamycin extends human life. If you want to see how people frame their own results against this backdrop, the sirolimus reviews and sirolimus before and after pages collect what users and small studies report, almost all of it biomarker or subjective, none of it survival data.

Why hasn't anyone run a human lifespan trial for rapamycin?

Because a human lifespan trial is enormously expensive and slow, and the incentive structure isn't there. Sirolimus went generic years ago (the brand Rapamune lost patent exclusivity in the 2010s), so there's no pharmaceutical company with a strong financial reason to fund a decades-long, multi-thousand-person trial in healthy people to prove an anti-aging effect. A trial powered to detect a mortality difference in healthy adults would need thousands of participants followed for many years, likely a decade or more, at a cost plausibly in the hundreds of millions of dollars. Compare that to the ITP mouse studies, which take roughly 3 years per cohort and cost a small fraction of that, and it's clear why the human data lags so far behind. The closest thing in progress is the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), an academic, crowd-funded study out of UCLA looking at low-dose intermittent rapamycin's effects on aging biomarkers, bone density, and frailty measures in adults 50 to 85, over 48 weeks . It is not measuring lifespan, and even its biomarker results were still being reported out in stages as of the mid-2020s. Nobody credible claims this trial, or any other currently running, will settle the human lifespan question.

How do people actually dose sirolimus off-label for longevity?

The off-label protocols people discuss are built around intermittent, low dosing, a deliberate departure from the daily, higher-dose regimens used in transplant medicine. The reasoning: intermittent dosing may hit mTORC1 hard enough to trigger the beneficial signaling shift, while giving the immune system recovery time between doses, since mTORC2 (a related complex tied more to metabolic and immune function) is thought to be less affected by pulsed dosing than by continuous exposure . Common patterns discussed in the self-experimentation and longevity-clinic literature involve once-weekly or once-every-two-weeks oral doses, often in a 4 to 10 mg range, individualized against blood trough levels drawn about a day after dosing. This is fundamentally different from the daily 1 to 5 mg (adjusted to a target blood trough of roughly 4-12 ng/mL) that transplant patients take under close monitoring ^[2]. There is no FDA-approved dosing schedule for this use, no standard protocol agreed upon across clinicians, and no long-term safety data on intermittent low-dose regimens in otherwise healthy people. Any specific number you see quoted online is a clinical opinion or a small-study extrapolation, not an approved standard. If you're evaluating whether this approach makes sense for you at all, is sirolimus worth it and sirolimus pros and cons lay out the tradeoff without pretending the dosing question is settled.

What are the real risks and side effects of sirolimus?

Because sirolimus is an immunosuppressant, the biggest risk category is infection susceptibility, even at low, intermittent doses. Transplant-dose data show clearly elevated risk of serious infections, and while the intermittent low-dose theory is that this risk is much smaller, that theory hasn't been tested in a dedicated safety trial in healthy people. Mouth ulcers (aphthous stomatitis) are one of the most commonly reported side effects even at low doses, showing up in a meaningful share of users in both the transplant literature and off-label reports. They're usually manageable but can be uncomfortable enough that people adjust dose or timing around them. Metabolic effects are the other major category. Sirolimus is associated with elevated LDL cholesterol and triglycerides, and in some cases impaired glucose tolerance or new-onset insulin resistance, effects documented in the FDA label for chronic transplant dosing ^[2]. This is a genuinely awkward irony for a drug being tested for metabolic longevity benefits: at higher chronic doses, it can push lipids and glucose in the wrong direction. Whether low-dose intermittent regimens meaningfully avoid this is an open question, not a settled one. Other documented effects in the label include impaired wound healing, elevated blood pressure, low blood counts, and rare but serious lung inflammation (interstitial lung disease) ^[2]. None of these are hypothetical; they're listed because they were observed in clinical use, just not necessarily at the doses and schedules longevity users are taking. | Risk category | Seen in transplant dosing (daily) | Reported with off-label low-dose/intermittent use |

Who should not take sirolimus?

People with active infections, a history of poor wound healing, uncontrolled high cholesterol or triglycerides, or anyone immunocompromised for another reason should treat sirolimus as high-risk or inappropriate without a specialist's direct involvement. Pregnant or breastfeeding people should not take it; sirolimus carries documented reproductive risk warnings on its FDA label ^[2]. Anyone with a planned surgery in the near future should flag sirolimus to their surgical team, since impaired wound healing is a labeled risk, and stopping the drug ahead of surgery is a common precaution in transplant medicine. More broadly, anyone considering this for longevity reasons should be honest that they're accepting real, labeled drug risks in exchange for an effect that is proven in mice and unproven in humans. That's not a reason nobody should ever try it, but it is a reason to do it under a prescriber's supervision with bloodwork, not by ordering pills off an unregulated website.

Does sirolimus interact with other medications or supplements?

Yes, and the interaction list matters because sirolimus is metabolized through the CYP3A4 liver enzyme pathway. Strong CYP3A4 inhibitors, including some antifungals (ketoconazole), certain antibiotics (erythromycin), and grapefruit juice, can raise sirolimus blood levels substantially, increasing side effect risk. Strong inducers of that pathway, like rifampin or St. John's Wort, can lower drug levels and reduce effectiveness ^[2]. Other immunosuppressants, live vaccines, and certain cholesterol medications also carry documented interaction warnings on the label. This is exactly why blood-level monitoring (checking trough levels) is standard practice in transplant dosing and is recommended by clinicians running off-label protocols too. Self-dosing without any bloodwork removes the one safety check that catches an interaction before it becomes a problem.

How is sirolimus different from other longevity drug candidates?

Metformin, acarbose, and rapamycin get lumped together often, but they work through different pathways and have very different evidence bases. Metformin lowers blood glucose and has large observational datasets in diabetics suggesting possible mortality benefits, but the dedicated TAME trial designed to test it for aging in non-diabetics has faced years of funding delays and hasn't reported results. Acarbose, an alpha-glucosidase inhibitor, has shown lifespan extension in the same NIA ITP mouse program, though generally with smaller effect sizes than rapamycin in most cohorts ^[5]. Rapamycin stands out for two reasons: the mouse effect size is larger and more consistently replicated across ITP cohorts than for most other tested compounds, and the mechanism (mTOR inhibition) is more directly tied to a well-understood, conserved aging pathway across species, from yeast to worms to mice. That's a stronger mechanistic story than most competitors have. It still hasn't closed the human evidence gap, which is the whole point of this guide.

Is sirolimus worth trying for longevity right now?

That's a personal risk calculation, not a settled scientific answer, and anyone telling you otherwise is overselling it in one direction or the other. The honest framing: you'd be taking an FDA-approved drug, off-label, based on very strong mouse data and a plausible mechanism, with real but generally manageable side effects at low intermittent doses, in exchange for a human longevity benefit that is currently unproven. Some people find that trade acceptable given the mouse data and mechanistic logic. Others reasonably decide that without a completed human trial showing mortality or healthspan benefit, the risk isn't justified yet. If you do decide to move forward, the responsible path is a prescriber who runs baseline labs (lipids, glucose, complete blood count, kidney function), monitors trough levels, and reassesses periodically, not a source that ships pills with no oversight. Sirolimus Rx works with a provider-reviewed process and a licensed fulfilling pharmacy partner specifically so that people who choose this path do it with bloodwork and medical oversight rather than guessing. For a fuller weighing of the case for and against, see sirolimus pros and cons and is sirolimus worth it.

What results or timeline should a beginner expect?

Nobody should expect to feel anything dramatic, and that's actually consistent with the mechanism. Rapamycin isn't a stimulant or a mood drug; its proposed benefits are about long-term risk reduction (of age-related disease processes) and cellular maintenance, not a subjective daily effect. Biomarker changes some users and small studies report, like shifts in inflammatory markers or lipid panels, can show up within weeks to a few months of starting a protocol, though the size and consistency of those shifts vary a lot between individuals and aren't the same as proof of a longevity benefit. If you want a sense of how people describe the arc of starting and staying on a protocol, sirolimus results timeline and sirolimus success rate go through what's actually being reported, separate from what's scientifically proven. The only honest timeline claim is this: there is no human data showing when, or whether, a longevity benefit appears at any point on any dosing schedule. Anyone giving you a specific month-by-month lifespan-benefit timeline in humans is speculating past the evidence.

Frequently asked questions

Is sirolimus the same thing as rapamycin?

Yes. Rapamycin was the original name for the compound, discovered in a soil bacterium found on Easter Island in the 1970s. Sirolimus is the name used on the FDA-approved drug label. They are chemically identical; the terms are used interchangeably in research and clinical settings.

Is sirolimus FDA-approved for anti-aging or longevity?

No. Sirolimus is FDA-approved for preventing organ transplant rejection, and in other formulations (Fyarro, Hyftor) for specific rare conditions. Any use for aging, longevity, or healthspan is entirely off-label, meaning it hasn't been reviewed or approved by the FDA for that purpose.

Has sirolimus been proven to extend human lifespan?

No completed human trial has measured lifespan or mortality as an outcome for sirolimus in healthy adults. The strongest evidence, showing 9-23% median lifespan extension, comes from the NIA's Interventions Testing Program in mice. Human trials so far are small, short, and use biomarkers, not survival, as endpoints.

What is the NIA Interventions Testing Program?

It's a National Institute on Aging-funded program testing candidate longevity compounds in genetically diverse mice across three independent labs (Jackson Laboratory, University of Michigan, UT Health Science Center), designed to catch effects that don't replicate. Rapamycin has shown consistent lifespan extension across multiple ITP cohorts since 2009.

Why hasn't a human lifespan trial for rapamycin been done yet?

Cost and time. A trial powered to detect a mortality effect in healthy adults would need thousands of participants followed for a decade or more, plausibly costing hundreds of millions of dollars, with no patent-holder incentivized to fund it since sirolimus is generic.

What is the PEARL trial and does it prove rapamycin extends lifespan?

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is an academic, crowd-funded UCLA study looking at low-dose intermittent rapamycin's effects on bone density, frailty, and aging biomarkers over 48 weeks in adults 50-85. It does not measure lifespan and isn't designed to.

What are the most common side effects of low-dose sirolimus?

Mouth ulcers are among the most frequently reported side effects even at low intermittent doses. Other documented risks include increased infection susceptibility, elevated cholesterol or triglycerides, impaired wound healing, and, rarely, lung inflammation, per the FDA label for chronic dosing.

How is off-label longevity dosing different from transplant dosing?

Transplant patients take sirolimus daily, dosed to a blood trough target around 4-12 ng/mL. Off-label longevity protocols typically use intermittent dosing, often weekly or every two weeks, at doses in the single digits of milligrams, aiming to hit mTORC1 while sparing mTORC2-related immune and metabolic function. Neither the doses nor the schedule are FDA-standardized.

Does sirolimus interact with grapefruit or other medications?

Yes. Sirolimus is metabolized by the CYP3A4 liver enzyme, so grapefruit juice, certain antifungals, and some antibiotics can raise blood levels and side effect risk. Drugs like rifampin or St. John's Wort can lower drug levels. Trough-level monitoring is the standard way to catch these interactions.

Who shouldn't take sirolimus?

People who are pregnant, have active infections, poor wound healing history, uncontrolled high lipids, or are already immunocompromised should avoid it or use it only under close specialist supervision. Anyone with planned surgery should discuss stopping it beforehand, since impaired wound healing is a labeled risk.

Can I just order sirolimus online without a doctor?

You can find unregulated sources online, but that skips bloodwork, trough-level monitoring, and interaction screening, the exact safeguards that catch problems early. A provider-reviewed process with a licensed pharmacy partner, checking baseline labs and following up periodically, is the safer route for a drug with this risk profile.

Does sirolimus help with metabolic health or make it worse?

Both are possible, and that's part of the unresolved evidence gap. Chronic higher-dose sirolimus is associated with elevated LDL, triglycerides, and sometimes impaired glucose tolerance per the FDA label. Whether low-dose intermittent regimens avoid this while still producing metabolic benefits hasn't been established in controlled human trials.

Sources

1. FDA, Rapamune (sirolimus) prescribing information: FDA-approved uses, dosing targets, and labeled risks including infection, lipid changes, wound healing impairment, and reproductive warnings
2. National Institute on Aging, mTOR and aging research overview: mTOR signaling and the Interventions Testing Program's role in testing rapamycin and other compounds for lifespan effects
3. Harrison et al., Nature 2009: Rapamycin fed late in life extended median lifespan by 9% in males and 14% in females in the original ITP cohort
4. Miller et al., Aging Cell, NIA ITP rapamycin dose-response cohorts: Later ITP cohorts found dose-dependent lifespan extension up to roughly 23% in some female mouse cohorts
5. Mannick et al., Science Translational Medicine 2014: An mTOR inhibitor improved influenza vaccine response in older adults in a 6-week trial, an immune biomarker outcome, not a lifespan outcome